Transpara 1.6 uses deep-learning algorithms to detect breast cancer in both 2D and 3D mammograms. The software grades mammograms on a 10-point scale that denotes short-term risk of cancer being present. Independent clinical validations show that the exam score can decrease a radiologist's workload, in particular reading time with 3D mammography, and assist them in triaging patients with respect to need for future investigation.
Transpara has the CE Mark for use with 2D mammography and 3D digital breast tomosynthesis (DBT) images from multiple vendors. The system has U.S. Food and Drug Administration (FDA) clearance for use with 2D mammography and is pending FDA clearance for use with 3D DBT. Currently, Transpara's deep-learning algorithms are being employed or piloted in about 20 countries across the globe, according to the company.